Compounds > metformin
Page last updated: 2024-10-30

metformin and Invasiveness, Neoplasm

metformin has been researched along with Invasiveness, Neoplasm in 74 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG."9.51Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. ( Chiong, E; Kesavan, E; Lata, RM; Mahendran, R; Ong, WYF; Shen, T; Sng, JH; Wang, Z, 2022)
"Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC)."8.02Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer. ( Dang, J; Gao, J; Hu, D; Jin, Z; Li, L; Li, W; Liu, X; Luo, Y; Ma, F; Sun, H; Wang, D; Wang, J, 2021)
" In this in vitro study, we hypothesized that metformin with an effective dose can inhibit tumor cell proliferation and metastasis by modulating the expressions of MMP-2 and -9 and interfering with NF-kB signaling in primary breast cancer cells (PBCCs)."8.02Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. ( Besli, N; Dilek Kancagi, D; Ekmekci, CG; Kanigur Sultuybek, G; Karagulle, OO; Ovali, E; Senol, K; Soydas, T; Tastan, C; Tuncdemir, M; Ulutin, T; Yaprak Sarac, E; Yenmis, G; Yilanci, M, 2021)
"High doses of metformin induces oxidative stress (OS) and transforming growth factor β1 (TGF-β1) in breast cancer cells, which was associated with increased cancer stem cell population, local invasion, liver metastasis and treatment resistance."7.96Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. ( Abdelhay, E; Binato, R; Borges, FH; Cecchini, AL; Cecchini, R; L Mencalha, A; Lopes, NMD; Luiz, RC; Marinello, PC; Panis, C; Rodrigues, JA; Silva, TNX, 2020)
" Here, we proposed to assess the anti-EMT abilities and explore the inherent pharmacological mechanisms of the classic hypoglycaemic agent metformin for colorectal cancer(CRC)."7.88The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC). ( Hu, L; Wang, Y; Wu, Z, 2018)
"This study aimed at investigating the effects of metformin on the growth and metastasis of esophageal squamous cell carcinoma (ESCC) in vitro and in vivo."7.88Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. ( Liang, F; Wang, C; Wang, YG, 2018)
"It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)."7.83Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016)
"We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression."7.83Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016)
"Metformin, a widely prescribed antidiabetic drug, has previously been shown to lower the risk of certain types of cancer, including that of breast cancer, and to improve prognosis."7.81Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. ( Fan, C; Liu, Z; Sun, Y; Wang, X; Wang, Y; Wei, G; Wei, J, 2015)
"Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism."7.81Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. ( Adekola, KU; Bajpai, R; Dalva-Aydemir, S; Kandela, I; Koblinski, JE; Martinez, M; Raje, NS; Rosen, ST; Shanmugam, M; Singhal, S; Wei, C, 2015)
" In the present study, we found that metformin inhibited cell migration and invasion of phorbol 12-myristate 13-acetate-induced MCF-7 and tamoxifen-resistant MCF-7 breast cancer cells."7.80Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. ( Cho, YH; Jang, SY; Kim, A; Kim, C; Kim, CH; Kim, JH; Kim, JK; Lee, JY, 2014)
"To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007."7.79Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kautzky-Willer, A; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Xylinas, E, 2013)
"Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells."7.79Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. ( Abbe, P; Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Cerezo, M; Giacchero, D; Lehraiki, A; Ohanna, M; Rocchi, S; Rouaud, F; Tartare-Deckert, S; Tichet, M, 2013)
"The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo."5.72Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model. ( Almeida, CP; da Silva, VHSR; de Araújo Campos, MR; de Carvalho, BA; de Souza Silva, FH; Del Puerto, HL; Ferreira, E; Lima, BM; Ribeiro, TS; Rocha, SA; Veloso, ES, 2022)
"Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG."5.51Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. ( Chiong, E; Kesavan, E; Lata, RM; Mahendran, R; Ong, WYF; Shen, T; Sng, JH; Wang, Z, 2022)
"Metformin attenuates the metastasis and autophagy in osteosarcoma."5.48Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. ( Bao, X; Guan, H; Li, F; Zhao, L, 2018)
"Melanoma is the most dangerous and treatment-resistant skin cancer."5.46Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. ( Albini, A; Argenziano, G; Ciarrocchi, A; Dallaglio, K; Dominici, M; Grisendi, G; Longo, C; Petrachi, T; Romagnani, A, 2017)
"Metformin is a potent antiproliferative and anti-metastatic agent against human CCA cells."5.46Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB. ( Cha'on, U; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Wongkham, C; Wongkham, S, 2017)
"Metformin is a widely used drug to treat patients with type II diabetes."5.43Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016)
"Metformin is an oral drug that has been widely used to treat type 2 diabetes mellitus."5.42Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. ( Chen, X; Hu, C; Hu, F; Shen, Y; Wang, J; Yu, P; Zhang, W, 2015)
"Metformin was also found to significantly inhibit the expression and secretion of MMP-9 and uPA in HCC cells, and suppress the phosphorylation of ERK1/2 and JNK1/2."5.40Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. ( Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF, 2014)
"Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity."5.40Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. ( Jiang, CC; Jiang, ZW; Li, HH; Liu, H; Sun, XJ; Zhang, P, 2014)
" In this in vitro study, we hypothesized that metformin with an effective dose can inhibit tumor cell proliferation and metastasis by modulating the expressions of MMP-2 and -9 and interfering with NF-kB signaling in primary breast cancer cells (PBCCs)."4.02Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. ( Besli, N; Dilek Kancagi, D; Ekmekci, CG; Kanigur Sultuybek, G; Karagulle, OO; Ovali, E; Senol, K; Soydas, T; Tastan, C; Tuncdemir, M; Ulutin, T; Yaprak Sarac, E; Yenmis, G; Yilanci, M, 2021)
"Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC)."4.02Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer. ( Dang, J; Gao, J; Hu, D; Jin, Z; Li, L; Li, W; Liu, X; Luo, Y; Ma, F; Sun, H; Wang, D; Wang, J, 2021)
"High doses of metformin induces oxidative stress (OS) and transforming growth factor β1 (TGF-β1) in breast cancer cells, which was associated with increased cancer stem cell population, local invasion, liver metastasis and treatment resistance."3.96Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. ( Abdelhay, E; Binato, R; Borges, FH; Cecchini, AL; Cecchini, R; L Mencalha, A; Lopes, NMD; Luiz, RC; Marinello, PC; Panis, C; Rodrigues, JA; Silva, TNX, 2020)
"The effect of metformin on different breast cancer cell lines, representing the molecular heterogenicity of the disease was investigated using in vitro proliferation and apoptosis assays."3.91PYK2 promotes HER2-positive breast cancer invasion. ( Al-Juboori, SI; Almshayakhchi, R; Ball, GR; Boocock, DJ; Caraglia, M; Desiderio, V; Idri, S; Miles, AK; Pearson, JR; Regad, T; Vadakekolathu, J; Wagner, S; Zafeiris, D, 2019)
" Here, we proposed to assess the anti-EMT abilities and explore the inherent pharmacological mechanisms of the classic hypoglycaemic agent metformin for colorectal cancer(CRC)."3.88The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC). ( Hu, L; Wang, Y; Wu, Z, 2018)
"This study aimed at investigating the effects of metformin on the growth and metastasis of esophageal squamous cell carcinoma (ESCC) in vitro and in vivo."3.88Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. ( Liang, F; Wang, C; Wang, YG, 2018)
" The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC)."3.85Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. ( Connolly, E; Crew, KD; Du, X; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, MA; Mundi, P; Refice, S; Taback, B; Yang, J; Zheng, T, 2017)
"We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression."3.83Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016)
"It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)."3.83Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016)
"These findings provide for the first time the evidence that metformin can block precancerous lesions progressing to invasive tumors through inhibiting the activation of STAT3 pathway, and may be used for treatment of the non-invasive bladder cancers to prevent them from progression to invasive tumors."3.81Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways. ( Bo, JJ; Gao, JX; Huang, YR; Lin, SL; Liu, MY; Liu, N; Liu, Q; Liu, SS; Pan, Q; Shen, RL; Yang, GL; Yang, JH; Zhang, LH, 2015)
" The antidiabetic drug metformin has been shown to display antitumoral properties in prostate cancer cell and animal models; however, its role in the formation of metastases remains poorly documented."3.81Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells. ( Ader, I; Bost, F; Cormont, M; Cuvillier, O; Dirat, B; Golzio, M; Larbret, F; Laurent, K; Lemichez, E; Malavaud, B; Massa, F; Mettouchi, A; Tanti, JF, 2015)
"Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism."3.81Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. ( Adekola, KU; Bajpai, R; Dalva-Aydemir, S; Kandela, I; Koblinski, JE; Martinez, M; Raje, NS; Rosen, ST; Shanmugam, M; Singhal, S; Wei, C, 2015)
"Metformin, a widely prescribed antidiabetic drug, has previously been shown to lower the risk of certain types of cancer, including that of breast cancer, and to improve prognosis."3.81Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. ( Fan, C; Liu, Z; Sun, Y; Wang, X; Wang, Y; Wei, G; Wei, J, 2015)
" Neurotensin (NTS) and its high affinity receptor (NTSR1) are up regulated in 20% of breast cancers, and NTSR1 overexpression was shown to predict a poor prognosis for 5 year overall survival in invasive breast carcinomas."3.80Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. ( Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z, 2014)
" In the present study, we found that metformin inhibited cell migration and invasion of phorbol 12-myristate 13-acetate-induced MCF-7 and tamoxifen-resistant MCF-7 breast cancer cells."3.80Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. ( Cho, YH; Jang, SY; Kim, A; Kim, C; Kim, CH; Kim, JH; Kim, JK; Lee, JY, 2014)
"Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells."3.79Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. ( Abbe, P; Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Cerezo, M; Giacchero, D; Lehraiki, A; Ohanna, M; Rocchi, S; Rouaud, F; Tartare-Deckert, S; Tichet, M, 2013)
"To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007."3.79Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kautzky-Willer, A; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Xylinas, E, 2013)
"Metformin treatment (median 20 days, range 7-34) was associated with a 17."2.82Measuring the biological effect of presurgical metformin treatment in endometrial cancer. ( Ali, S; Crosbie, EJ; Gilmour, K; Kitchener, HC; Kitson, S; McVey, R; Pemberton, P; Renehan, AG; Roberts, C; Sivalingam, VN, 2016)
"Metformin dose was escalated from 500 mg (in the first week) to 1000 mg twice daily in the second week."2.80Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. ( Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH, 2015)
"At the time of diagnosis, almost 80% of pancreatic cancer patients present with new-onset type 2 diabetes (T2D) or impaired glucose tolerance."2.79Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. ( Andersson, R; Karnevi, E; Rosendahl, AH, 2014)
"Preclinical data suggest that current breast cancer treatment strategies lead to CSC enrichment, contributing to chemotherapy and radiotherapy resistance, although a strong correlation with clinical parameters and prognosis is yet to be established."2.48The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. ( Economopoulou, P; Kaklamani, VG; Siziopikou, K, 2012)
"The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo."1.72Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model. ( Almeida, CP; da Silva, VHSR; de Araújo Campos, MR; de Carvalho, BA; de Souza Silva, FH; Del Puerto, HL; Ferreira, E; Lima, BM; Ribeiro, TS; Rocha, SA; Veloso, ES, 2022)
"Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D."1.62Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes. ( Ahtikoski, A; Arima, R; Karihtala, P; Puistola, U; Urpilainen, E, 2021)
"EMTs facilitate bladder cancer (BC) metastasis development, but the mechanism by which high-glucose levels promote these EMTs in BC remains unclear."1.56Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ. ( Chen, H; Li, S; Lin, Q; Xia, J; Xu, R; Zhang, F; Zhu, H, 2020)
"Metformin can inhibit the PI3K/Akt signaling pathway and synergizes with Nelfinavir to inhibit the proliferation and invasion of cervical cancer cells."1.56iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin. ( Cai, Y; He, Z; Xia, C; Yang, F, 2020)
"Metformin has an inhibitory effect on lung cancer and regulates the expression of certain microRNAs, but there is no report connecting metformin with microRNA-7 in lung cancer."1.56Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells. ( Chen, D; Chen, L; Dong, J; Liu, J; Peng, H; Wu, W; Yang, X; Zhao, Y, 2020)
"Metformin use was an independent prognostic factor of overall survival, cancer recurrence, and peritoneal recurrence."1.51The Effect of Metformin on Prognosis in Patients With Locally Advanced Gastric Cancer Associated With Type 2 Diabetes Mellitus. ( Jung, YJ; Kim, JH; Lee, HH; Park, CH; Seo, HS, 2019)
"Metformin treatment also significantly reduced tumor formation in vivo as well as protein expression of PCNA, Akt, Myc, and serine phosphorylation of the latter 2, which can be partially blocked by O/E α4 or sh-PP2Ac."1.51Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A. ( Jiang, W; Lin, X; Liu, J; Liu, S; Mao, X; Xu, L; Zhang, Z; Zhou, H; Zhou, X, 2019)
"Hypoglycemia is associated with local invasion and angiogenesis, whereas hyperglycemia promotes metastatic colonization."1.48Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. ( Akkan, J; Benitz, S; Bruns, P; Ceyhan, GO; Cheng, T; Friess, H; Hofmann, T; Huang, P; Jäger, C; Jastroch, M; Jian, Z; Kleeff, J; Kleigrewe, K; Kong, B; Lamp, D; Maeritz, N; Michalski, CW; Nie, S; Raulefs, S; Shen, S; Shi, K; Steiger, K; Zhang, Z; Zou, X, 2018)
"Treatment with metformin also suppressed tumor growth, invasion and EMT in LSL‑KrasG12D/+, Trp53fl/+and Pdx1‑Cre (KPC) transgenic mice that harbor spontaneous pancreatic cancer."1.48Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. ( Cao, J; Chen, K; Cheng, L; Duan, W; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Qin, T; Xiao, Y; Zhou, C, 2018)
"Metformin attenuates the metastasis and autophagy in osteosarcoma."1.48Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. ( Bao, X; Guan, H; Li, F; Zhao, L, 2018)
"Metastasis is the primary cause of death in prostate cancer (PCa) patients."1.48Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control. ( Antognelli, C; Cecchetti, R; Peirce, MJ; Riuzzi, F; Talesa, VN, 2018)
"To explore the effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS, 24 patients with gastric cancer were tracked for treatment."1.46Effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS. ( Wu, X, 2017)
"Herein, we reveal that breast cancer cells that preferentially metastasize to the lung or bone display relatively high expression of PGC-1α compared with those that metastasize to the liver."1.46PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. ( Andrzejewski, S; Annis, MG; Chénard, V; Johnson, RM; Klimcakova, E; McGuirk, S; Northey, JJ; Papadopoli, DJ; Siegel, PM; Sriram, U; St-Pierre, J; Tabariès, S, 2017)
"Metformin is an antidiabetic drug used in treatment of type 2 diabetes."1.46Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner. ( Shamsara, M; Valaee, S; Yaghoobi, MM, 2017)
"Metformin is a potent antiproliferative and anti-metastatic agent against human CCA cells."1.46Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB. ( Cha'on, U; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Wongkham, C; Wongkham, S, 2017)
"Melanoma is the most dangerous and treatment-resistant skin cancer."1.46Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. ( Albini, A; Argenziano, G; Ciarrocchi, A; Dallaglio, K; Dominici, M; Grisendi, G; Longo, C; Petrachi, T; Romagnani, A, 2017)
"We propose that metformin represses prostate cancer EMT and metastasis through targeting the COX2/PGE2/STAT3 axis."1.46Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. ( Jiang, J; Jiang, Y; Lan, W; Liu, G; Liu, Q; Tong, D; Xiao, H; Xu, J; Zhang, D, 2017)
"Metformin treatment reduced N-cadherin and increased E-cadherin expression in both CF41 and TGF-β1sh cells."1.46Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. ( Bajgelman, MC; Borin, TF; de Campos Zuccari, DA; de Carvalho Ferreira, L; Leonel, C; Moschetta, MG; Viloria-Petit, AM, 2017)
"In endometriosis and endometrial cancer, LSR was observed not only in the subapical region but also throughout the lateral region as well as in normal endometrial epithelial cells in the secretory phase, and LSR in the cancer was reduced in correlation with the malignancy."1.43The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells. ( Hatakeyama, T; Kohno, T; Kojima, T; Konno, T; Saito, T; Satohisa, S; Shimada, H; Takahashi, S; Tsujiwaki, M, 2016)
"Metformin is a widely used drug to treat patients with type II diabetes."1.43Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016)
"Metformin treatment decreased cell growth of PCa cell line 22Rv1 and stalled cells at the G1/S checkpoint in a time- and dose-dependent manner, resulting in increased cells in G1 (P < 0."1.43Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells. ( Bapat, B; Fleshner, N; Garcia, J; White-Al Habeeb, NM, 2016)
"Esophageal cancer is one of the most aggressive tumor types because of its invasiveness and metastatic potential."1.43Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. ( Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakanuma, S; Nakayama, A; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T, 2016)
"Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress."1.42Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. ( Bansal, N; Bertino, JR; DiPaola, RS; Mishra, PJ; Stein, M, 2015)
"Metformin is an oral drug that has been widely used to treat type 2 diabetes mellitus."1.42Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. ( Chen, X; Hu, C; Hu, F; Shen, Y; Wang, J; Yu, P; Zhang, W, 2015)
"However, the anti-tumor mechanism in prostate cancer remains unclear."1.42Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. ( Furuya, Y; Kato, H; Koike, H; Miyazawa, Y; Sekine, Y; Suzuki, K, 2015)
"Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity."1.40Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. ( Jiang, CC; Jiang, ZW; Li, HH; Liu, H; Sun, XJ; Zhang, P, 2014)
"In the AR(+) LNCaP prostate cancer cells, we found that metformin inhibits androgen-induced CRE activity and IGF-IR gene transcription."1.40Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. ( Belfiore, A; Maggiolini, M; Malaguarnera, R; Migliaccio, A; Morcavallo, A; Morrione, A; Sacco, A; Squatrito, S, 2014)
"Metformin was also found to significantly inhibit the expression and secretion of MMP-9 and uPA in HCC cells, and suppress the phosphorylation of ERK1/2 and JNK1/2."1.40Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. ( Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF, 2014)
"Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, which is, in part, due to intrinsic (de novo) and extrinsic (acquired) resistance to conventional therapeutics, suggesting that innovative treatment strategies are required for overcoming therapeutic resistance to improve overall survival of patients."1.38Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. ( Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z, 2012)
"Metformin therefore has the potential to be a potent anti-cancer drug in therapeutic strategies for fibrosarcoma metastasis."1.36Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/act ( Hwang, YP; Jeong, HG, 2010)

Research

Studies (74)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's60 (81.08)24.3611
2020's14 (18.92)2.80

Authors

AuthorsStudies
Veloso, ES1
de Carvalho, BA1
de Souza Silva, FH1
Ribeiro, TS1
Lima, BM1
Almeida, CP1
da Silva, VHSR1
Rocha, SA1
de Araújo Campos, MR1
Del Puerto, HL1
Ferreira, E1
Ottone, T1
Silvestrini, G1
Piazza, R1
Travaglini, S1
Gurnari, C1
Marchesi, F1
Nardozza, AM1
Fabiani, E1
Attardi, E1
Guarnera, L1
Divona, M1
Ricci, P1
Irno Consalvo, MA1
Ienzi, S1
Arcese, R1
Biagi, A1
Fiori, L1
Novello, M1
Mauriello, A1
Venditti, A1
Anemona, L1
Voso, MT1
Dong, S1
Ruiz-Calderon, B1
Rathinam, R1
Eastlack, S1
Maziveyi, M1
Alahari, SK1
Seo, HS1
Jung, YJ1
Kim, JH2
Lee, HH1
Park, CH1
Dong, J1
Peng, H1
Yang, X1
Wu, W2
Zhao, Y1
Chen, D1
Chen, L1
Liu, J4
Xia, C1
Yang, F1
He, Z1
Cai, Y1
Li, J3
Chen, H3
Wang, R1
Li, P2
Miao, Y1
Liu, P1
Shao, S1
Zhao, L3
An, G1
Zhang, L1
Jing, X1
Luo, M1
Li, W2
Meng, D1
Ning, Q1
Zhao, X2
Lei, J2
Li, S3
Zhu, H1
Xia, J1
Zhang, F2
Xu, R1
Lin, Q1
Wang, Z4
Ong, WYF1
Shen, T1
Sng, JH1
Lata, RM1
Mahendran, R1
Kesavan, E1
Chiong, E1
Marinello, PC1
Panis, C1
Silva, TNX1
Binato, R1
Abdelhay, E1
Rodrigues, JA1
L Mencalha, A1
Lopes, NMD1
Borges, FH1
Luiz, RC1
Cecchini, R1
Cecchini, AL1
Sa, G1
Li, L3
He, S1
Wu, T1
Dang, J1
Gao, J2
Ma, F1
Luo, Y1
Wang, J2
Wang, D1
Sun, H2
Liu, X1
Hu, D1
Jin, Z1
Urpilainen, E1
Arima, R1
Karihtala, P1
Puistola, U1
Ahtikoski, A1
Yenmis, G1
Yaprak Sarac, E1
Besli, N1
Soydas, T1
Tastan, C1
Dilek Kancagi, D1
Yilanci, M1
Senol, K1
Karagulle, OO1
Ekmekci, CG1
Ovali, E1
Tuncdemir, M1
Ulutin, T1
Kanigur Sultuybek, G1
Valaee, S1
Yaghoobi, MM1
Shamsara, M1
Yang, Y2
Wu, XH1
Zheng, F1
Wu, J1
Tang, Q1
Xiao, Q1
Hann, SS1
Andrzejewski, S1
Klimcakova, E1
Johnson, RM1
Tabariès, S1
Annis, MG1
McGuirk, S1
Northey, JJ1
Chénard, V1
Sriram, U1
Papadopoli, DJ1
Siegel, PM1
St-Pierre, J1
Wu, X1
Tyszka-Czochara, M1
Lasota, M1
Majka, M1
Antognelli, C1
Cecchetti, R1
Riuzzi, F1
Peirce, MJ1
Talesa, VN1
Xu, T1
Li, D1
He, Y2
Qiao, M1
Chen, Y1
Bao, X1
Guan, H1
Li, F1
Insin, P1
Prueksaritanond, N1
Wandee, J1
Prawan, A1
Senggunprai, L1
Kongpetch, S1
Tusskorn, O1
Kukongviriyapan, V1
Duan, W2
Qian, W1
Zhou, C1
Cao, J1
Qin, T1
Xiao, Y1
Cheng, L1
Chen, K2
Li, X2
Ma, J2
Ma, Q2
Wang, Y3
Wu, Z4
Hu, L1
Tong, L1
Song, Y1
Sun, J1
Shi, J1
Diao, Y1
Li, Y2
Jian, Z1
Cheng, T1
Zhang, Z2
Raulefs, S1
Shi, K1
Steiger, K1
Maeritz, N1
Kleigrewe, K1
Hofmann, T1
Benitz, S1
Bruns, P1
Lamp, D1
Jastroch, M1
Akkan, J1
Jäger, C1
Huang, P1
Nie, S1
Shen, S1
Zou, X1
Ceyhan, GO1
Michalski, CW1
Friess, H1
Kleeff, J1
Kong, B1
Liang, F1
Wang, YG1
Wang, C1
Zhou, X1
Liu, S1
Lin, X1
Xu, L1
Mao, X1
Jiang, W1
Zhou, H2
Ferretti, AC1
Hidalgo, F1
Tonucci, FM1
Almada, E1
Pariani, A1
Larocca, MC1
Favre, C1
Al-Juboori, SI1
Vadakekolathu, J1
Idri, S1
Wagner, S1
Zafeiris, D1
Pearson, JR1
Almshayakhchi, R1
Caraglia, M1
Desiderio, V1
Miles, AK1
Boocock, DJ1
Ball, GR1
Regad, T1
Koh, M1
Lee, JC1
Min, C1
Moon, A1
Cerezo, M1
Tichet, M1
Abbe, P1
Ohanna, M1
Lehraiki, A1
Rouaud, F1
Allegra, M1
Giacchero, D1
Bahadoran, P1
Bertolotto, C1
Tartare-Deckert, S1
Ballotti, R1
Rocchi, S1
Rieken, M2
Xylinas, E2
Kluth, L2
Crivelli, JJ1
Chrystal, J1
Faison, T1
Lotan, Y2
Karakiewicz, PI2
Fajkovic, H2
Babjuk, M1
Kautzky-Willer, A2
Bachmann, A2
Scherr, DS2
Shariat, SF2
Trinh, QD1
Lee, RK1
Novara, G1
Margulis, V1
Martinez-Salamanca, JI1
Matsumoto, K1
Seitz, C1
Remzi, M1
Briganti, A1
Malaguarnera, R1
Sacco, A1
Morcavallo, A1
Squatrito, S1
Migliaccio, A1
Morrione, A1
Maggiolini, M1
Belfiore, A1
Karnevi, E1
Andersson, R1
Rosendahl, AH1
Sun, XJ1
Zhang, P1
Li, HH1
Jiang, ZW1
Jiang, CC1
Liu, H1
Jang, SY1
Kim, A1
Kim, JK1
Kim, C1
Cho, YH1
Kim, CH1
Lee, JY1
Yan, L1
Zhou, J1
Gao, Y1
Ghazal, S1
Lu, L1
Bellone, S1
Liu, N2
Santin, AD1
Taylor, H1
Huang, Y1
Hsieh, SC1
Tsai, JP1
Yang, SF1
Tang, MJ1
Hsieh, YH1
Dupouy, S1
Doan, VK1
Mourra, N1
De Wever, O1
Llorca, FP1
Cayre, A1
Kouchkar, A1
Gompel, A1
Forgez, P1
Dirat, B1
Ader, I1
Golzio, M1
Massa, F1
Mettouchi, A1
Laurent, K1
Larbret, F1
Malavaud, B1
Cormont, M1
Lemichez, E1
Cuvillier, O1
Tanti, JF1
Bost, F1
Dalva-Aydemir, S1
Bajpai, R1
Martinez, M1
Adekola, KU1
Kandela, I1
Wei, C1
Singhal, S1
Koblinski, JE1
Raje, NS1
Rosen, ST1
Shanmugam, M1
Kato, H1
Sekine, Y1
Furuya, Y1
Miyazawa, Y1
Koike, H1
Suzuki, K1
Fan, C1
Liu, Z1
Sun, Y1
Wang, X1
Wei, G1
Wei, J1
Bansal, N1
Mishra, PJ1
Stein, M1
DiPaola, RS1
Bertino, JR1
Kordes, S1
Pollak, MN1
Zwinderman, AH1
Mathôt, RA1
Weterman, MJ1
Beeker, A1
Punt, CJ1
Richel, DJ1
Wilmink, JW1
Chen, X2
Hu, C1
Zhang, W2
Shen, Y1
Hu, F1
Yu, P1
Pan, Q1
Yang, GL1
Yang, JH1
Lin, SL1
Liu, SS1
Liu, MY1
Zhang, LH1
Huang, YR1
Shen, RL1
Liu, Q2
Gao, JX1
Bo, JJ1
Gandhy, SU1
Imanirad, P1
Jin, UH1
Nair, V1
Hedrick, E1
Cheng, Y1
Corton, JC1
Kim, K1
Safe, S1
Guo, Z1
Cao, M1
You, A1
Li, H1
Cui, Y1
Fang, F1
Song, T1
Li, Q1
Zhu, X1
Zhang, T1
Sivalingam, VN1
Kitson, S1
McVey, R1
Roberts, C1
Pemberton, P1
Gilmour, K1
Ali, S2
Renehan, AG1
Kitchener, HC1
Crosbie, EJ1
Wahdan-Alaswad, R1
Harrell, JC1
Fan, Z1
Edgerton, SM1
Liu, B1
Thor, AD1
Shimada, H1
Satohisa, S1
Kohno, T1
Takahashi, S1
Hatakeyama, T1
Konno, T1
Tsujiwaki, M1
Saito, T1
Kojima, T1
Peng, T1
Zhang, K1
Lin, C1
Han, R1
Lu, C1
Park, J1
Kim, WG1
Enomoto, K1
Willingham, M1
Cheng, SY1
Kalinsky, K1
Zheng, T1
Hibshoosh, H1
Du, X1
Mundi, P1
Yang, J1
Refice, S1
Feldman, SM1
Taback, B1
Connolly, E1
Crew, KD1
Maurer, MA1
Hershman, DL1
White-Al Habeeb, NM1
Garcia, J1
Fleshner, N1
Bapat, B1
Nakayama, A1
Ninomiya, I1
Harada, S1
Tsukada, T1
Okamoto, K1
Nakanuma, S1
Sakai, S1
Makino, I1
Kinoshita, J1
Hayashi, H1
Oyama, K1
Miyashita, T1
Tajima, H1
Takamura, H1
Fushida, S1
Ohta, T1
Jiang, Z1
Sun, L1
Xu, Q1
Han, L1
Wang, F1
Wu, E1
Ma, Z1
Yang, SH1
Lu, G1
Xue, H1
Kim, DH1
Zhu, JJ1
Liu, Y1
Saengboonmee, C1
Seubwai, W1
Cha'on, U1
Sawanyawisuth, K1
Wongkham, S1
Wongkham, C1
Petrachi, T1
Romagnani, A1
Albini, A1
Longo, C1
Argenziano, G1
Grisendi, G1
Dominici, M1
Ciarrocchi, A1
Dallaglio, K1
Tong, D1
Liu, G1
Xu, J1
Lan, W1
Jiang, Y1
Xiao, H1
Zhang, D1
Jiang, J1
Leonel, C1
Borin, TF1
de Carvalho Ferreira, L1
Moschetta, MG1
Bajgelman, MC1
Viloria-Petit, AM1
de Campos Zuccari, DA1
Hwang, YP1
Jeong, HG1
Tan, BK1
Adya, R1
Chen, J1
Lehnert, H1
Sant Cassia, LJ1
Randeva, HS1
Bao, B1
Ahmad, A1
Azmi, AS1
Sarkar, SH1
Banerjee, S1
Kong, D1
Thakur, S1
Sarkar, FH1
Wu, B1
Sheng, L1
Zhu, J1
Gu, L1
Shen, H1
La, D1
Hambly, BD1
Bao, S1
Di, W1
Economopoulou, P1
Kaklamani, VG1
Siziopikou, K1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gemcitabine, Erlotinib and Metformin in Patients With Locally Advanced and Metastatic Pancreatic Cancer[NCT01210911]Phase 2120 participants (Actual)Interventional2010-08-31Completed
Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation[NCT00930579]Phase 235 participants (Actual)Interventional2009-10-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Tumor Proliferation in Tumor Specimens

This outcome measure examines the changes in tumor proliferation as measured by the amount of Ki-67 protein in the tumor. (NCT00930579)
Timeframe: Baseline, up to 4 weeks

Interventionpercentage of ki-67 positive cells (Mean)
Premetformin Tumor SamplePost Metformin Tumor Sample
Metformin2.172.165

Reviews

1 review available for metformin and Invasiveness, Neoplasm

ArticleYear
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.
    The oncologist, 2012, Volume: 17, Issue:11

    Topics: Aldehyde Dehydrogenase 1 Family; Breast Neoplasms; CD24 Antigen; Cell Differentiation; Cell Transfor

2012

Trials

4 trials available for metformin and Invasiveness, Neoplasm

ArticleYear
Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer.
    Singapore medical journal, 2022, Volume: 63, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Diabetes Mellitus; Disease Progre

2022
Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.
    Immunology and cell biology, 2014, Volume: 92, Issue:6

    Topics: CD11c Antigen; Cell Line, Tumor; Coculture Techniques; Diabetes Mellitus, Type 2; Female; Glucose; H

2014
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Pr

2015
Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
    British journal of cancer, 2016, Feb-02, Volume: 114, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carcinoma, Endometrioid; Endometrial Hyperplasia;

2016

Other Studies

69 other studies available for metformin and Invasiveness, Neoplasm

ArticleYear
Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model.
    Scientific reports, 2022, 10-22, Volume: 12, Issue:1

    Topics: Animals; Cadherins; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Epithelial-Mesenchymal

2022
Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
    Leukemia, 2023, Volume: 37, Issue:12

    Topics: Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans;

2023
Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
    International journal of cancer, 2020, 05-01, Volume: 146, Issue:9

    Topics: Animals; Antigens, Polyomavirus Transforming; Cell Transformation, Neoplastic; Female; Hypoglycemic

2020
The Effect of Metformin on Prognosis in Patients With Locally Advanced Gastric Cancer Associated With Type 2 Diabetes Mellitus.
    American journal of clinical oncology, 2019, Volume: 42, Issue:12

    Topics: Adult; Aged; Cause of Death; Cohort Studies; Comorbidity; Databases, Factual; Diabetes Mellitus, Typ

2019
Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells.
    Anti-cancer drugs, 2020, Volume: 31, Issue:4

    Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Gen

2020
iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 123

    Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; HeLa Cells; Humans; Metformi

2020
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell N

2020
Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020, Volume: 34, Issue:8

    Topics: Adenylate Kinase; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CXCL1

2020
Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:18

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Culture Media;

2020
Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis.
    Pathology, research and practice, 2020, Volume: 216, Issue:10

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Female; Gene

2020
In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma.
    European journal of pharmacology, 2021, Jan-15, Volume: 891

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, T

2021
Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer.
    Cell biology international, 2021, Volume: 45, Issue:5

    Topics: Adult; Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2021
Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes.
    Anticancer research, 2021, Volume: 41, Issue:2

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Finland; Humans;

2021
Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity.
    Acta histochemica, 2021, Volume: 123, Issue:4

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Neoplasm Invasivene

2021
Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: beta Catenin; Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Ex

2017
Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:8

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Male; Metformin; Neoplasm Invasiveness; Pho

2017
The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:1

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Berberine; Cell Cycle Checkpoints; Cell Line, Tumor; C

2018
PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.
    Cell metabolism, 2017, Nov-07, Volume: 26, Issue:5

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Energy Metabolism; Female; Humans; Hypog

2017
Effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:5(Special)

    Topics: Apoptosis; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Cisplatin; Dose-Response Rel

2017
Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
    International journal of molecular sciences, 2018, Jan-16, Volume: 19, Issue:1

    Topics: Biomarkers, Tumor; Caffeic Acids; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Cell Adhesion; Ce

2018
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:5

    Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchyma

2018
Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
    World journal of surgical oncology, 2018, Mar-20, Volume: 16, Issue:1

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; F

2018
Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma.
    Cell death & disease, 2018, 05-23, Volume: 9, Issue:6

    Topics: Adolescent; Adult; Animals; Autophagy; Autophagy-Related Protein 12; Base Sequence; Cell Line, Tumor

2018
Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes
    Asian Pacific journal of cancer prevention : APJCP, 2018, May-26, Volume: 19, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Diabetes Mellitus, Typ

2018
Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
    Life sciences, 2018, Aug-15, Volume: 207

    Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Cycle; Ce

2018
Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
    Oncology reports, 2018, Volume: 40, Issue:3

    Topics: Animals; Apoptosis; Autocrine Communication; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell M

2018
The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC).
    European journal of pharmacology, 2018, Sep-05, Volume: 834

    Topics: Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; HCT116 C

2018
Long noncoding RNA H19 participates in metformin-mediated inhibition of gastric cancer cell invasion.
    Journal of cellular physiology, 2019, Volume: 234, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell

2019
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
    Cellular and molecular gastroenterology and hepatology, 2018, Volume: 6, Issue:4

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core

2018
Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 51, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation

2018
Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A.
    Medical science monitor : international medical journal of experimental and clinical research, 2019, Jan-29, Volume: 25

    Topics: A549 Cells; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Proli

2019
Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration.
    Scientific reports, 2019, 02-26, Volume: 9, Issue:1

    Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelia

2019
PYK2 promotes HER2-positive breast cancer invasion.
    Journal of experimental & clinical cancer research : CR, 2019, May-22, Volume: 38, Issue:1

    Topics: Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; F

2019
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
    Bioorganic & medicinal chemistry, 2013, Apr-15, Volume: 21, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Ani

2013
Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:8

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Enz

2013
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
    BJU international, 2013, Volume: 112, Issue:8

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Disease Progression; Disease-Free Survival; Female; Foll

2013
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:1

    Topics: Aged; Carcinoma, Transitional Cell; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycem

2014
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
    Endocrinology, 2014, Volume: 155, Issue:4

    Topics: Androgens; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Membrane; CREB-Binding Protein;

2014
Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma; Cell Li

2014
Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells.
    Anticancer research, 2014, Volume: 34, Issue:8

    Topics: Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinase

2014
Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation.
    Oncogene, 2015, Jun-04, Volume: 34, Issue:23

    Topics: Cell Line, Tumor; Cell Movement; DNA Methylation; Endometrial Neoplasms; Female; Gene Expression Reg

2015
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Amino acids, 2014, Volume: 46, Issue:12

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinas

2014
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cel

2014
Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:2

    Topics: Actin Cytoskeleton; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12;

2015
Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease

2015
Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
    Biochemical and biophysical research communications, 2015, May-22, Volume: 461, Issue:1

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulati

2015
Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.
    International journal of molecular medicine, 2015, Volume: 36, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell

2015
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
    Oncotarget, 2015, Jun-20, Volume: 6, Issue:17

    Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line

2015
Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:12

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell

2015
Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.
    Journal of experimental & clinical cancer research : CR, 2015, Aug-07, Volume: 34

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival;

2015
Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC.
    Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cell Survival;

2015
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Cancer science, 2016, Volume: 107, Issue:4

    Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene E

2016
Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
    Cell cycle (Georgetown, Tex.), 2016, Volume: 15, Issue:8

    Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Claudins; Disease-Free Surv

2016
The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Adiponectin; Berberine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Endome

2016
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor;

2016
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Adenocarcinoma, Follicular; Anaplasia; Animals; Antineoplastic Agents; Cell Proliferation; Diet, Hig

2016
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:2

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfilt

2017
Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
    The Prostate, 2016, Volume: 76, Issue:16

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epigenesis

2016
Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Prolifera

2016
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Cancer letters, 2017, 01-28, Volume: 385

    Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

2017
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Mov

2016
Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
    Anticancer research, 2017, Volume: 37, Issue:1

    Topics: AMP-Activated Protein Kinases; Anoikis; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor

2017
Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
    Oncotarget, 2017, Jan-24, Volume: 8, Issue:4

    Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2017
Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
    Cancer letters, 2017, 03-28, Volume: 389

    Topics: Aged; Animals; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelia

2017
Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model.
    Journal of mammary gland biology and neoplasia, 2017, Volume: 22, Issue:1

    Topics: Animals; Cadherins; Cell Line, Tumor; Cell Movement; Dogs; Epithelial-Mesenchymal Transition; Mammar

2017
Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/act
    British journal of pharmacology, 2010, Volume: 160, Issue:5

    Topics: Calcium; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Drug Screening Assays, A

2010
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:3

    Topics: Adult; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cyclic AMP; Cyclic

2011
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
    Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Ce

2012
Metformin inhibits the development and metastasis of ovarian cancer.
    Oncology reports, 2012, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell

2012